ホーム › 肝臓がん（肝細胞がん） › ニューヨーク
ニューヨークにおける肝臓がん（肝細胞がん）の臨床試験
ニューヨーク内の拠点で、肝臓がん（肝細胞がん）に関する33件の研究が参加者を募集しています。
ニューヨーク内の都市
公式研究テキスト（英語）
A Study of ZW251 in Participants With Advanced Solid Tumors
- Memorial Sloan Kettering Cancer Center, New York
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/05更新 · NCT07164313A Phase 1 Study of the Safety and Tolerability of CTX-10726
- START New York, Lake Success
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07419841Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
- Exelixis Clinical Site #76, Syracuse
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- Research Facility, New York
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06726161National Liver Cancer Screening Trial
- The Feinstein Institutes, Northwell Health, Inc., Manhasset
被験者募集中第4相
18歳〜85歳 · 全性別 · 2026/09/25更新 · NCT06084234A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Local Institution - 0100, Mineola
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07291076Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- Columbia University Irving Medical Center, New York
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06915753A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Memorial Sloan Kettering Cancer Center Mskcc, New York
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT06427941Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- NYU Langone Health, New York
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- 他2件
被験者募集中観察研究
22歳以上 · 全性別 · 2026/09/11更新 · NCT06486454GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
- Montefiore Einstein Comprehensive Cancer Center, The Bronx
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/10更新 · NCT04864054Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, New York
- Research Site, New York
- Research Site, New York
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06921785Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- New York Cancer & Blood Specialists, New York
- University of Rochester - Wilmot Cancer Institute, Rochester
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/27更新 · NCT06582017Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Memorial Sloan Kettering Cancer Center, New York
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05919264Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- Northwell Health/Center for Advanced Medicine, Lake Success
- Mount Sinai Hospital, New York
- Montefiore Medical Center-Einstein Campus, The Bronx
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT07166406A Study of MGC026 in Participants With Advanced Solid Tumors
- START-New York Long Island, Lake Success
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06242470HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
- Montefiore Medical Center, The Bronx
被験者募集中
18歳以上 · 全性別 · 2026/08/11更新 · NCT06899152A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
- Clinical Research Alliance, Inc, Westbury
- 他1件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06330064Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- Roswell Park Cancer Institute, Buffalo
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05168163Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
- Icahn School of Medicine at Mount Sinai, New York
被験者募集中第4相
18歳以上 · 全性別 · 2026/07/28更新 · NCT07059494A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
被験者募集中第2相
8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, New York
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/17更新 · NCT06600321Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- VA NY Harbor Healthcare System, New York, NY, New York
- James J. Peters VA Medical Center, Bronx, NY, The Bronx
被験者募集中
18歳〜75歳 · 全性別 · 2026/06/17更新 · NCT05486572A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- Memorial Sloan Kettering Cancer Center, New York
被験者募集中第1相
16歳以上 · 全性別 · 2026/06/02更新 · NCT07197554DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA04-0, New York
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/22更新 · NCT06953089A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Memorial Sloan Kettering Cancer Center - New York, New York
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/27更新 · NCT05440708Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Roswell Park Comprehensive Cancer Center, Buffalo
- Montefiore Medical CenterMontefiore Medical Park, The Bronx
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/02更新 · NCT05733598Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
- Montefiore Medical Center, The Bronx
被験者募集中第2相
18歳以上 · 全性別 · 2026/01/20更新 · NCT05366829HOPE Against Cancer Recurrence in HCC
- Rutgers New Jersey Medical School (New York), New York
被験者募集中第4相
18歳以上 · 全性別 · 2025/12/16更新 · NCT06717919A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 107, New York
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/11/21更新 · NCT05914116SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Buffalo
- Massive Bio SYNERGY-AI site, Hempstead
- Massive Bio SYNERGY-AI site, Manhasset
- 他2件
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774The Dragon PLC Trial (DRAGON-PLC)
- Memorial Sloan Kettering Cancer Center, New York
被験者募集中
18歳以上 · 全性別 · 2025/05/15更新 · NCT06914648A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Memorial Sloan-Kettering Cancer Center, New York
被験者募集中第1/2相
18歳以上 · 全性別 · 2024/11/25更新 · NCT05824975ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。